Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit enough to tolerate FCR therapy, should be superior candidates for that latter, With all the benefit staying that this therapy may be accomplished in six months whilst ibrutinib should be taken indefinitely. This selection